reason report
yupelri provid breath fresh
bottom line ahead novemb pdufa date provid
preview op /therav op yupelri revefenacin
publish updat market model yupelri novel once-
daili nebul lama treatment moderate-to-sever chronic
obstruct pulmonari diseas copd believ
revenu year patient requir
long act nebul therapi abl use laba despit
lama prefer base global initi chronic lung
diseas gold guidelin yupelri meaning advantag
nebul lama sunovion lonhala magnair
once-daili treatment option vs twice-daili yupelri compat
standard jet nebul lonhala requir specif magnair
devic although believ time approv novemb
essenti assum yupelri nevertheless repres key asset
therav reiter op
expect nebul lama realiz strong uptak
nebul copd market despit two nebul laba therapi
sunovion brovana perforomist sale
medacorp physician indic still unmet need
laba less prefer lama address copd even among
patient current nebul laba physician note
patient take inhal lama spiriva address
compon despit understand inhal would
optim efficaci patient popul believ
larg proport current nebul laba popul
either incorpor switch onto nebul lama therapi
estim proport get long run
among two nebul lama believ yupelri
meaning advantag lonhala magnair once-daili
dose patient current multipl medic therefor
physician see once-daili dose yupelri present notabl
advantag complianc vs twice-daili dose lonhala
devic compat patient current nebul laba use
standard jet nebul yupelri would compat
devic contrast lonhala util separ devic magnair
physician believ unlik patient would get two
differ nebul treatment therefor believ yupelri
meaning product profil advantag lonhala long term
believ take market share compar lonhala
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
complet octob edt distribut octob edt rx trend deriv im
leerink therav price target increas
updat yupelri analysi therav co-commerci yupelri
unit state receiv product us net profit
estim yupelri worth therav
compani total valuat term rel valuat therav
econom interest yupelri compani third import asset
behind trelegi royalti stream local jak inhibitor
clinic develop updat yupelri revenu forecast larg
similar slightli previou estim absolut dollar
biggest varianc first full launch year new estim
vs prior new estim
prior estim howev assum longer period
us market exclus versu prior assumpt year
therefor long-term yupelri estim significantli higher versu
prior estim total chang increas price target
reiter outperform rate therav
leerink mylan valuat impact neglig chang
yupelri estim yupelri contribut total ep
estim chang revis market
model yupelri neglig impact estim
price target nevertheless believ yupelri approv
import one help off-set headwind us gener
epipen believ yupelri becom revenu product
compani
provid detail review yupelri opportun start
page updat market model page updat
compani model therav page
yupelri provid breath fresh therav
estim minimum spent copd medic unit state
accord american colleg chest physician spend medic care
copd
 estim least figur come inpati outpati
medic inclus inhal nebul solut medic
iqvia report sale copd outpati inhal nebul solut
reflect rebates/ discount
copd patient diagnos anoth undiagnos
copd type lung diseas character progress loss lung function
main symptom short breath cough/wheez sputum
short period intensifi diseas activ known exacerb play larg role copd
exposur tobacco smoke air pollut lead caus copd along genet
copd mortal rate high
copd third lead caus death
copd frequent treat pharmaceut inhal nebul form
mild moder high sever
avoid toxic particl
influenza
spiromet use
note trial copd inhal nebul
common primari endpoint improv baselin
placebo adjust forc expiratori volum
air patient forcibl blow second fulli
inhal measur ml chang common basi
compar copd product
medacorp specialist feedback chron obstruc pulm diseas chron obstruct pulm diseas
within copd pharmaceut pulmonologist prefer long act muscarin
global initi chronic lung diseas gold
guidelin recommend lama type copd
guidelin place patient group
base symptom risk wide follow
pulmonologist
guidelin recommend patient group
take lama first-lin treatment either
monotherapi combin therapi
long act beta agonist laba inhal
medacorp specialist feedback indic gold
specialist comment payer begun
prefer lama monotherapi laba monotherapi
demonstr authorit gold
one specialist explain laba view
compar efficaci lama work faster
lama laba prefer may
result tachycardia fast heart rate
patient sever
treatment patient
medacorp specialist feedback global initi chronic obstruct lung diseas new england journal medicin
gold guidelin provid specif treatment algorithm differ group
copd patient group receiv lama part first-lin treatment
lama laba
medacorp specialist feedback global initi chronic obstruct lung diseas
lama clearli prefer drug choic patient use/ne
nebul lama nebul avail recent
almost prescript lama
prescript
major patient use inhal deliveri
prescript
entir laba
lama
nebul
approv
lot
patient also
laba combo
laba inhal nebul solut
three inhal data set indic copd asthma spiriva respimat serev foradil number product scale adjust
fact provid accur pictur copd prescript
base physician feedback believ target patient popul
nebul larger share today
ideal patient candid nebul
patient unabl use inhal often
elderli patient
intoler dri powder
copd patient abl use inhal prefer
nebul perhap psycholog reinforc
physic act oper machin
wit mist give patient comfort
medic effect
percent copd popul
mylan/therav develop yupelri revefenacin first once-daili
nebul lama use standard nebul devic
long act nebul treatment copd
yupelri key advantag lonhala
compat standard jet nebul devic
unlik sunovion lonhala use proprietari devic magnair
yupelri use standard nebul
potenti avoid complic use two separ devic also cost
patient combo treatment laba lama nebul
howev yupelri would second market lama nebul year behind sunovion
lonhala said uptak lonhala slow far trend total trx
compar two nebul laba trend
medacorp feedback suggest unmet need daili lama
product work standard nebul
lama laba
given choic nebul lama laba copd
would definit choos lama patient harm
fast heart rate similar efficaci laba work faster
lama mainten therapi laba rescu therapi
gold guidelin recommend lama first-lin
treatment follow extens field pulmonolog
patient prefer standard devic
easi use
proprietari devic come chanc
patient follow instruct properli lama use
standard nebul welcom chang
reson pulmonologist
follow revefenacin think repres step-up
lonhala magnair alreadi prescrib
patient
encourag revefenacin me-too drug
reincarn older gener drug common copd
revefenacin see clear benefit patient use
inhal need lama
yupelri clinic profil competit versu lonhala lama market
pivot studi data long act nebul treatment copd
common
common
common
common placebo
placebo
common
wk pbo
forc expiratori volum one second measur show amount air person forc exhal one second test
lp research therav compani present journal copd fda label lonhala brovana perforomist
medacorp feedback suggest definit market differenti
nebul product yupelri
also subset copd
patient requir
nebul prefer
patient use inhal
capabl use inhal still want use
revenu revefenacin
could gener fraction
combin revenu brovana
would logic choic model revefenacin market share
look brovana perforomist lonhala launch year
could also draw revenu spiriva user mayb
would switch revefenacin base see
practic individu need nebul lama
lp model yupelri
anticip current laba nebul user either add/switch
lama nebul yupelri take share nebul lama sub-market
conserv model nebul lama opportun deriv exist
estim nebul laba perforomist brovana sale therefor
believ sale nebul lama would unlik meaning outperform total
potenti upsid nebul share sinc recent nebul lama
avail therefor market could expand current closer believ
difficult given cost consider nebul treatment typic expens inhal counterpart
believ two key factor drive uptak lama nebul
patient current nebul laba drop switch inhal laba get nebul
lama medacorp specialist indic give lama laba treatment patient ideal given
cost two brand nebul treatment would prefer lama nebul option
patient current nebul laba add nebul lama patient typic
nebul laba use inhal address lama compon use best abil
avail nebul lama would allow improv usag patient cost
prohibit would expect patient nebul laba lama therapi
see lama use extens popul yupelri captur major market
long term believ brand brovana/perforomist user incorpor nebul lama
therapi way
brovana/perforomist go gener believ percentag increas get
gener nebul laba brand nebul lama would less cost prohibit patient
believ yupelri captur share nebul lama market due superior product profil
composit matter patent expir assum yupelri suit addit ip
may maintain us market exclus past year assum
medacorp specialist feedback global initi chronic obstruct lung diseas new england journal medicin
lp model yupelri
believ yupelri achiev meaning uptak nebul
copd space fend competit lonhala
trx
medacorp feedback suggest recent reimburs trend could favor
sometim difficult pulmonologist
get laba reimburs like
laba less promin gold guidelin payer
pay exampl everi time tri use
brovana get pushback patient get
inhal lama ic
get letter payer forc patient switch
copd therapi includ latest formulari
file except happen
get call payer often question choic
prescript often forc patient tri spiriva
laba howev never insur question
nebul prescript probabl due lower price
point nebul drug would also surpris patient
tri spiriva nebul lama genuin
need nebul obtain clinic benefit
unawar addit nebul lama develop
one els develop nebul lama could identifi nebul market appear
lower prioriti industri given small target popul subset
lama product develop program inhal format
present focu copd tripl therapi dri powder inhal
inhal combin lama laba ic one devic elimin need multipl devic
compani includ gsk/therav trelegi ellipta astrazeneca
approv
sever risk could potenti undermin forecast yupelri
although payer gener prefer lama risk yupelri gain wide formulari adopt
lonhala avail sinc april uptak appear slow septemb compar
perforomist brovana yupelri could face slow initi uptak
specialist also receiv call insur question choic copd prescript usual must
patient step tri spiriva first order obtain author anoth product
long act nebul copd treatment market continu declin rather increas
nebul laba market declin appear trend high-singl digit y/i volum declin
could reduc opportun nebul lama believ deriv exist nebul lama
lonhala magnair could perform better expect model
shorter time deliv medic may make lonhala prefer vs yupelri
yupelri may get time approv novemb
sunovion receiv complet respons letter may abl address fda question
got drug approv decemb
sunovion disclos detail believ relat drug-devic combo
novel magnair devic would expect issu yupelri given util standard
medacorp specialist feedback lp research new england journal medicin
mylan/therav negoti incom split revefenacin
februari therav enter agreement
revefenacin develop commerci follow term
net incom share
therav net incom share
royalti therav rest world
double-digit mid-teen
up-front payment therav
up-front equiti invest therav jan
elig mileston payment dec
efficaci safeti data copd treatment includ meta analysi data
fev improv
lp research octob journal copd fda prescrib inform clinicaltri gov therav compani present
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver
could expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr
gener copaxon may improv biosimilar neulasta may slower estim
rate share outperform therav biotechnolog compani form via
spin-out thrx divers set asset robust engin
previous produc sever fda approv drug includ anoro breo vibativ
leverag deep expertis drug deliveri compani late earli stage
pipelin product oper via proven mechanisms-of-act aim differenti
either beneficial/us mode administr revefenacin better safeti /- wider
therapeut window one commerci product vibativ
nich antibiot commerci potenti fallen well short compani expect
tbph revefenacin nebul formul long act muscarin antagonist lama w/
posit phase data patient partner op compani anticip
potenti us approv receiv signific share profit product
commerci passiv recipi stand earn net
royalti sale gsk close tripl trelegi recent approv
us europ prior medacorp survey work suggest success close tripl could
becom stapl copd standard-of-car model suggest tripl could becom
blockbust opportun temper slower-than-expect launch breo/
anoro still forecast ww tripl sale peak beyond tbph commercial/
partner asset compani also develop improv jak inhibitor jaki partner
op inflammatori bowel diseas ibd norepinephrin serotonin reuptak
inhibitor nsri neurogen orthostat hypotens noh drug
leverag novel deliveri uniqu compound proven mechanisms-of-act could
offer superior safeti and/or treatment effect wider therapeut window
estim price target month use dcf analysi
discount rate termin growth rate discount rate consist
model biotech de-risk ph asset multipl program
develop higher risk aldr valuat inclus
net cash
investor face multipl risk includ limit
commerci risk vibativ seen modest uptak thu far
commerci risk gsk trelegi close tripl combin well clinic risk label
signific clinic risk earli stage program given stage develop
partnership risk maxim opportun inflammatori bowel
develop risk sinc exploratori phase ii data enter pivot
dilut risk model equiti rais
believ could impact stock significantli
sale
anticip brand gener prescript brovana perforomist nebul
total prescript brand brovana perforomist
brand brovana perforomist script
use lama form treatment lama monotherapi combin
make chang treatment
brand brovana perforomist script
use lama form treatment lama monotherapi combin
make chang treatment
total prescript gener brovana perforomist
gener brovana perforomist script
use lama form treatment lama monotherapi combin
make chang treatment
gener brovana perforomist script
use lama form treatment lama monotherapi combin
make chang treatment
total brovana perforomist script brand gener use lama
form treatment
split market script use lama form treatment
split market script use lama form treatment
 revenu revefenacin
compani report leerink partner research
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
herceptin approv launch
neulasta approv launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
equival
chang
chg work cap
share outstand includ option warrant
